AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

 AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

Shots:

  • The companies have signed an 18mos. supply agreement under a 3yrs. master supply and development agreement. Oxford Biomedica to receive $17.95M up front as a capacity reservation fee and expects to receive additional revenue of $41.89M + materials costs for the manufacturing of multiple large-scale batches of AZD1222 until the end of 2021
  • Oxford Biomedica will reserve capacity for ~3 manufacturing suites in the Oxbox, for an initial 18mos. period. The new GMP facility is suitable for manufacturing viral vectored vaccines and gene therapy vectors up to 1,000-liter scale.
  • The companies may extend the supply period for AZD1222 by a further 18mos. into 2022 and 2023 by mutual agreement. The agreement follows the supply agreement b/w the companies signed on May 28, 2020 for exclusively manufacture AZD1222 at 200L scale and associated process development

Click here ­to­ read full press release/ article | Ref: Oxford Biomedica | Image: Yahoo Sports

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post